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Rooibos (Aspalathus linearis) and 
Honeybush (Cyclopia spp.): From 
Bush Teas to Potential Therapy for 
Cardiovascular Disease
Shantal Windvogel
Abstract
Cardiovascular disease (CVD) is a leading cause of worldwide deaths. A num-
ber of risk factors for cardiovascular disease as well as type 2 diabetes and stroke 
present as the metabolic syndrome. Metabolic risk factors include hypertension, 
abdominal obesity, dyslipidaemia and increased blood glucose levels and may also 
include risk factors such as vascular dysfunction, insulin resistance, low high den-
sity lipoprotein (HDL) cholesterol levels and inflammation. Rooibos (Aspalathus 
linearis) and honeybush (Cyclopia spp.) are indigenous South African plants whose 
reported health benefits include anti-tumour, anti-inflammatory, anti-obesity, anti-
oxidant, cardioprotective and anti-diabetic properties. The last two decades have 
seen worldwide interest and success for these plants, not only as health beverages 
but also as preservatives, flavourants and skincare products. This review will focus 
on the current literature supporting the function of these plants as nutraceuticals 
capable of potentially reducing the risk of cardiovascular disease.
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1. Introduction
Cardiovascular disease is the leading cause of deaths worldwide, killing 
17.9 million people in 2016 [1]. While the number of cardiovascular disease related 
morbidity and mortality in the developed world has decreased or remained steady, 
the developing world has seen an increase. Limited resources, poverty, poor access 
to affordable healthcare, poor implementation of health policies, as well as poor 
education may be some of the reasons for the increase in cardiovascular diseases 
in low to middle income countries [2]. A number of risk factors for cardiovascu-
lar disease as well as type 2 diabetes and stroke present as metabolic syndrome. 
Metabolic risk factors include hypertension, abdominal obesity, dyslipidaemia, 
increased blood glucose levels, and may also include risk factors such as vascular 
dysfunction, insulin resistance, low levels of high density lipoprotein cholesterol 
(HDL-C) and inflammation. Natural products could play a significant role in drug 
discovery and development with examples including morphine, isolated from the 
opium poppy (Papaver somniferum) and artemisinin, from Artemisia afra [3–5]. 
Nutraceuticals are foods or supplements with health benefits [6]. To this end, a 
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number of nutraceuticals including fruits, vegetables, tea and herbal infusions have 
shown health benefits. Approximately 80% of the emerging world relies on herbal 
supplements [7]. This may often be a more accessible form of health or self-care, 
due to a lack of access to modern medicine, an alternative to modern medicine or 
due to the high cost of treatment of modern medicine. This practice may involve the 
use of herbs or plants, including polyphenol rich rooibos (Aspalathus linearis) and 
honeybush (Cyclopia spp.), indigenous South African plant species with reported 
health benefits [8]. Many nutraceuticals contain polyphenols, the most abundant 
antioxidants in the diet which could help in the prevention of neurodegenerative 
diseases, diabetes, cancer, and cardiovascular disease [9]. Oxidative stress is a key 
process occurring in these diseases and is marked by imbalances between oxidants 
and the availability of antioxidants as well as perturbations in redox signalling 
mechanisms [10, 11]. Drugs used in the treatment of cardiovascular disease and 
obesity often have side effects, hence there is a need for better tolerated, safer 
and more natural treatment options [12]. A number of epidemiological studies 
and meta-analyses show some cardiovascular benefits with the intake of tea [13]. 
Furthermore, a review of some clinical studies show benefits of tea consumption in 
reducing cardiovascular risk factors, especially in overweight or obese subjects [14]. 
Rooibos and honeybush have a number of reported health properties, many of them 
targeting risk factors for the development of cardiovascular disease. The purpose of 
this paper was to review the role of rooibos and honeybush as potential nutraceuti-
cals in the treatment of cardiovascular disease.
2. Risk factors for cardiovascular disease
A multitude of risk factors predispose to the onset of cardiovascular disease. This 
includes unmodifiable risk factors, such as increasing age, male gender, ethnicity, 
family history and genetics [15]. Modifiable risk factors include tobacco smoking, an 
unhealthy diet, a sedentary lifestyle, high alcohol intake, high blood pressure, being 
overweight or having central obesity, dyslipidaemia, impaired glucose tolerance or 
diabetes [15]. Diabetes not only quadrupled from 1980 to 2014 but approximately 
57% of diabetic women and 67% of diabetic men are likely to present with cardio-
vascular disease by the age of 50 [1, 16]. Metabolic syndrome is largely preventable 
and includes a number of clinical findings which when occurring together, increase 
the risk of diabetes and cardiovascular disease. These include central obesity with 
any of the following risk factors including increased triglycerides, fasting plasma 
glucose, blood pressure and reduced HDL cholesterol levels [17]. Metabolic syn-
drome is also accompanied by changes in neuroendocrine and autonomic function 
[18]. It is known that early life stressors can predispose to disease outcome in later 
life, including cardiovascular disease [19]. Chronic stress influences cardiovascular 
outcome and anxiety and depression are also risk factors for cardiovascular dis-
ease [20–22]. This leads to changes in glucocorticoids and mineralocorticoids via 
modulation of the hypothalamic pituitary axis (HPA) [18]. Xenobiotics, including 
drugs and herbal infusions are metabolised by drug metabolising enzymes such 
as the phase I, cytochrome P450 system, which also influences the formation of 
steroid hormones [23]. CYP21A2 are precursors to both mineralocorticoids such as 
aldosterone and glucocorticoids such as cortisol and cortisone. Interestingly, rooibos 
flavonoids aspalathin and nothofagin inhibits CYP21A2 but not CYP11B1, which is 
responsible for converting 11-deoxycortisol to cortisol [24]. Substrate conversion of 
CYP117A1 and CYP21A2 was also inhibited by rooibos but other flavonoids such as 
rutin, orientin and vitexin were unable to inhibit CYP21A2. Rutin, under forskolin-
induced stress, was the best inhibitor of steroid production followed by nothofagin 
3Rooibos (Aspalathus linearis) and Honeybush (Cyclopia spp.): From Bush Teas to Potential…
DOI: http://dx.doi.org/10.5772/intechopen.86410
and vitexin and lastly by aspalathin and nothofagin [24]. The observed effects 
for steroid inhibition were attributed to structural differences in these rooibos 
flavonoids. Rooibos also decreased rat glucocorticoids by decreasing the corticos-
terone, deoxycorticosterone as well as the corticosterone: testosterone ratio [25]. In 
the accompanying human study the cortisol: corticosterone ratio was reduced by 
rooibos, which also inhibited 11 β-hydroxysteroid dehydrogenase type 1 (11βHSD1). 
This enzyme catalyses the conversion of cortisone to cortisol and is associated with 
risk factors for cardiovascular disease [26]. In a stress model using steroid producing 
H295R cells, rooibos and rutin were able to reduce cortisol levels. The inhibition of 
mineralocorticoid and glucocorticoid steroids by rooibos and the dihydrochalcones 
aspalathin and nothofagin were also demonstrated in H295R cells [27]. This suggests 
that rooibos may offer a possible therapeutic role in the management of cardio-
vascular complications relating from stress, by altering the biosynthesis of steroid 
hormones via the HPA axis. Inhibition of 11βHSD1 has been suggested as a potential 
target mechanism for drugs to modulate the metabolic syndrome; therefore, this 
could be further explored in the context of rooibos or even honeybush. The car-
diovascular complications of metabolic syndrome include coronary artery disease, 
peripheral vascular disease, hypertension as well as heart failure [28]. Primary 
management of metabolic syndrome is structured around lifestyle and dietary 
changes, including regular physical activity and a modest 5–10% initial reduction in 
caloric intake, failing which the use of pharmaceutical drugs may also be prescribed 
[17]. Approximately 1.9 billion people were overweight in 2016, of which 650 mil-
lion people were obese [29]. A sedentary lifestyle, excess calories, a high fat diet and 
genetics contribute to the development of obesity, which is characterised by a body 
mass index greater (BMI) >30 kg/m2 [30]. Urbanisation and a reduction in physical 
activity, along with an energy-rich Western diet, have contributed to the increase in 
cardiovascular disease in developing countries [31]. As a largely preventable dis-
order, obesity increases the risk of type 2 diabetes mellitus, cancer, cardiovascular 
disease, infertility, respiratory illnesses and a number of other health issues. In fact, 
obesity is not only a major independent risk factor but also an independent predic-
tor for cardiovascular disease [32]. Strategies to avoid unnecessary deaths could 
include therapeutics that are safe, easily accessible and cost-effective. Rooibos and 
honeybush are relatively safe but long term clinical studies considering their safety 
are lacking [33, 34]. Two clinical case reports recommended caution in rooibos 
consumption but patients had consumed infusions containing rooibos and other 
herbs, thus the effects of these preparations and potential interactions between 
them need to be considered [35, 36]. Rooibos and honeybush are caffeine free and 
have low tannin levels making them ideal beverages for health conscious people, 
pregnant women and young children [37–39]. These plants may therefore be viable 
options in the future, provided sufficient evidence is generated to support their use 
as nutraceuticals capable of reducing cardiovascular risk.
3. Origin, distribution and markets for rooibos and honeybush
Rooibos [Aspalathus linearis L. (Burm.f.) R. Dahlgren (Leguminosae)] is a 
member of the fynbos biome, which contains needle-like leguminous plants. It 
occurs in the Cederberg area of the Western Cape, and in South Africa it is one of the 
most widely consumed herbal teas or tisanes. Its marketing potential was realized by 
Benjamin Gunzberg in 1904 and since then its popularity has steadily risen worldwide 
[40]. The top five export markets for rooibos are Germany, Japan, the Netherlands, 
the United Kingdom and the United States of America [41]. Rooibos is used as herbal 
infusion, health beverage, an ingredient in skin care products and cosmetics as well 
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as a flavourant and colouring agent in a number of food applications. Honeybush 
(Cyclopia spp.), another member of the fynbos biome, is a bushy shrub found 
between the Piketberg area in the West, and Port Elizabeth in the East of South Africa 
(Figure 1). The year 1996 welcomed the first commercial harvests for honeybush, 
followed by the establishment of the South African Honeybush Tea Association 
(SAHTA) to manage the farming and sustainability practices as well as commercial 
interests of honeybush. After harvesting of rooibos or honeybush crops, leaves and 
stems are cut into small pieces, moistened and are fermented, either on open heaps 
or alternatively for honeybush also using an oven or fermentation tank. This is 
followed by drying of the fermented rooibos or honeybush. Fermentation of these 
plants is however associated with a change in phenolic composition as well as colour 
compared, to the green or unfermented plants which undergoes considerably less 
oxidation [42, 43]. The main contributors to the commercial market out of the 24 spe-
cies of Cyclopia are C. intermedia, C. genistoides and C. subternata. C. intermedia has 
the largest market share; however, it is harvested from the wild, making the future 
sustainability and profitability of the crop problematic [44]. Honeybush is a budding 
commercial interest, used mainly as a tisane with great potential for development and 
is exported to countries such as the Netherlands, Germany and Japan [45].
4. Polyphenols that may be responsible for beneficial effects
Polyphenols are secondary plant metabolites commonly occurring in the diet in 
tea, coffee, wine, fruit, vegetables and cereals. The four main types of polyphenols, 
namely stilbenes, phenolic acids, flavonoids and lignins, can be classified according to 
the number of polyphenol rings and various chemical groups associated with the rings 
[46]. Flavonoids share a C3-C6-C3 backbone and the classification system includes 
groups such as the flavonols, flavones, isoflavones, flavanones, antho-cyanidins, and 
flavanols [46]. A number of studies have reported a reduction in the risk of cardiovas-
cular disease with the intake of polyphenols [47]. The most prevalent polyphenols in 
rooibos include aspalathin, nothofagin, orientin, iso-orientin, vitexin and isovitexin, 
isoquercitrin and rutin [48, 49]. Aspalathin and aspalalinin are two unique dihydro-
chalcones in rooibos, with the former having been widely researched to date for its 
antioxidant and other health promoting properties [50, 51]. The flavonoid precursor 
in rooibos, Z-2-(β-ᴅ-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG), has also 
received considerable attention for its anti-diabetic properties [52]. In Cyclopia species, 
the xanthones mangiferin, isomangiferin and the flavanone hesperidin are predomi-
nant [43, 53]. Mangiferin is not unique to honeybush, and also occurs in mangoes 
(Mangifera indica) and plants such as Pyrrosia sheareri and Anemarrhena asphodeloides 
[54–56]. Bioavailability refers to the amount of the substance that is ingested that is 
available for metabolism [46]. It involves a number of processes, including intestinal 
absorption, plasma kinetics, metabolism, binding to plasma albumin and excretion 
Figure 1. 
Honeybush plant in flower. Image courtesy of the SAHTA.
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by the liver and kidneys [46]. Factors affecting bioavailability include isomeric form, 
processing methods, the type of compound and matrices surrounding the compound. 
The bioavailability of rooibos and honeybush is poor [57, 58]. The potential benefits 
attributed to their intake may therefore be hampered by poor bioavailability and also 
affect their maximal efficacy. Recently, the use of nanoencapsulation methods have 
been explored in order to increase the bioavailability and stability of aspalathin which 
could possibly promote the use of more effective nutraceuticals [59]. Since fermenta-
tion reduces polyphenol content, a number of studies have explored the benefits 
of unfermented, green rooibos or so called aspalathin rich extracts of rooibos in an 
attempt to elucidate the health promoting properties of the tisane [60, 61]. Others have 
looked at the effects of single isolate polyphenols from rooibos and honeybush such 
as aspalathin and mangiferin, to explore their functional benefits and identify a more 
targeted therapeutic option (Figure 2) [63, 64].
5. Antioxidant effects
Oxidative stress occurs due to an imbalance in the production of reactive oxygen 
species (ROS) and the availability of ROS scavengers. This may occur due to an excess of 
unstable reactive species including free radicals, such as reactive oxygen, reactive 
chlorine, reactive nitrogen and non-radical species, all of which may interact with cells, 
causing cellular damage [65]. Oxidative stress contributes to the pathobiology of cancer, 
cardiovascular disease, ageing, diabetes and atherosclerosis; therefore, it is plausible that 
dietary sources of antioxidants may be useful in reducing oxidative stress. Aerobic 
organisms are therefore reliant on innate antioxidant defences, e.g., superoxide dis-
mutase (SOD), catalase (CAT), glutathione peroxidase (GPX), reduced glutathione 
(GSH), uric acid, albumin and peroxiredoxins, to deal with large quantities of ROS in an 
attempt to reduce oxidative stress. Mitochondria are key generators of ROS in aerobic 
organisms, producing them as they generate energy; however, ROS are also important in 
cell signalling and released by macrophages to promote immunological attacks [66]. 
Xenobiotics, including rooibos and honeybush, are metabolised by the cytochrome 
P450 family and in the process, radicals are also produced and further detoxification 
processes facilitate their removal [67]. In cardiovascular disease, oxidative stress may 
manifest as dysfunction in the vascular endothelium or cardiac myocytes, and may arise 
due to increased intracellular Ca2+ as a result of ROS [68]. Oxidative stress associated 
with hyperglycaemia may occur from the glycation of proteins and the formation of 
advanced glycation end products, the auto-oxidation of glucose and the polyol pathway. 
Figure 2. 
Chemical structures of aspalathin (a) and mangiferin (b) showing phenol rings [62].
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In rodent models of streptozotocin (STZ)-induced diabetes, rooibos exerted antioxidant 
effects through increases in the activity of superoxide dismutase, catalase, glutathione 
peroxidase and decreasing lipid peroxidation [64, 69, 70]. Rooibos also decreased 
advanced glycation end products but clinical markers of diabetes such as fructosamine, 
glycated haemoglobin and glucose were unaffected [70]. Nuclear factor erythroid 
2-related factor 2 (Nrf2), a critical regulator of the antioxidant response of the cell, 
facilitates the removal of oxidants through increased antioxidant enzyme activity [67]. 
The regulator of Nrf2, Kelch-like ECH-associated protein 1 (Keap 1), has oxidative and 
electrophilic sensitive cysteine residues which upon activation allows for dissociation 
and activation of Nrf2 [71]. In H9c2 cardiomyocytes, aspalathin (1 μM) increased the 
expression of Nrf2, and antioxidant genes and enzymes, including SOD, CAT, GPX and 
peroxiredoxins [64]. The expression of cytoprotective genes including heme oxygenase 
1 (H0-1), NAD(P)H dehydrogenase (quinone 1), uncoupling protein 2 and apoptotic 
genes such as B-cell lymphoma 2 (Bcl-2) were also increased after aspalathin treatment. 
Uncoupling protein (UCP)3 and caspase 8, were however decreased. This suggests 
cellular survival due to reduced caspase 8, an important trigger for cell death [72]. UCP3 
and UCP2 act in concert in the mitochondrial antioxidant response with UCP2 appear-
ing to play a greater cytoprotective role in cardiomyocytes [73]. In the diabetic (db/db) 
mouse model, aspalathin increased Nrf2 expression as well as its downstream gene 
targets [74]. High dose aspalathin (130 mg/kg) also ameliorated the effects of hypergly-
caemia in the heart by reducing the expected left ventricular enlargement. It could not 
however reduce fasting plasma glucose levels compared to metformin in these mice. The 
study confirmed the role of Nrf2 in the antioxidant response of the cell, strengthened 
the case for the potential use of nutraceuticals such as aspalathin in the treatment of 
diabetes, and also provides evidence for the differential effects observed with isolates 
compared to whole extracts of plants. Oxidative stress and inflammation co-exists in a 
number of diseases. The relationship between the two appears complex and is suggested 
to be a possible reason why antioxidant supplements in clinical trials have been unsuc-
cessful [75]. In humans, no clear evidence of the antioxidant effects of flavonoids or 
pro-oxidant effects exist [76]. Supplementation of six cups of rooibos per day over a 
6 week period in adults with increased cardiovascular risk increased plasma total 
polyphenols, reduced glutathione (GSH), and increased the GSH: oxidized glutathione 
(GSSG) ratio compared to the control period [77]. Furthermore, TBARS and conjugated 
dienes were reduced, indicating a reduction in oxidative stress after rooibos consump-
tion. Ferric reducing antioxidant power (FRAP), oxygen radical absorbance capacity 
(ORAC) and 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonate (ABTS) were unaf-
fected. It is however known that assays for the measurement of antioxidant status can be 
difficult to compare and may also be non-specific and complicated by the instability of 
the species they are measuring [78]. Flavanoids and other polyphenols in honeybush are 
responsible for its antioxidant effects [79]. Fermentation of honeybush and rooibos 
however reduces antioxidant activity [80]. Mangiferin was the most effective scavenger 
of ABTS˙+ and in terms of its ability to reduce ferric ion, than the flavanone eriocitrin or 
the flavone luteolin [43]. This could be due to the hydrophilic nature of mangiferin, 
which is a glucoside. In an in vitro study using skin cells, aqueous extracts of Cyclopia 
subternata sp. exhibited the highest ABTS˙+ scavenging ability compared to other 
unfermented species of rooibos and Camellia sinensis [53]. In addition, rooibos, honey-
bush and Chinese green tea demonstrated ferric reducing antioxidant power (FRAP) 
and oxygen radical absorbance capacity (ORAC) abilities. Rooibos and honeybush also 
had better ORAC values than green tea, while rooibos aqueous extracts had the highest 
FRAP. In another model using hairless SKH-1 mice, unfermented honeybush and 
mangiferin had the highest FRAP compared to the fermented honeybush and hesperi-
din, and also the highest total antioxidant capacity [63]. Fermented and unfermented 
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honeybush as well as mangiferin and hesperidin also protected against ultraviolet (UV) 
B-induced lipid peroxidation. Fermented and unfermented extracts of honeybush as 
well as hesperidin increased SOD and CAT activity, while mangiferin increased SOD but 
not catalase activity [63]. When Chinese green tea, rooibos and honeybush were 
evaluated for their ability to reduce lipid peroxidation, unfermented extracts generally 
offered better protection against lipid peroxidation but green tea offered the highest 
level of protection compared to the other infusions [53]. Mangiferin activated phospha-
tidylinositol 3-kinase (PI3K) induced protein kinase b (PKB/Akt) and Nrf2 signalling 
pathways, thus decreasing oxidative stress in an in vivo model using human kidney cells 
exposed to tert-butyl hydroperoxide [81]. The activities of SOD, CAT, GPX and the 
non-enzymatic intracellular antioxidant GSH were also enhanced and lipid peroxidation 
was decreased. When compared to vitamin C, ROS scavenging ability as measured by 
the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging method and FRAP was 
decreased at lower concentrations compared to vitamin C, which was used as the 
positive control. The expression of Nrf2, HO-1, SOD, Akt and GSK-β and the mechanis-
tic target of rapamycin (mTOR) and cyclin D were also increased by exposure to 
mangiferin. In an STZ-induced diabetic Wistar rat model, mangiferin improved 
antioxidant status and reduced apoptosis and inflammation [82]. This could be due to 
modulation of the AGE-RAGE/MAPK signalling pathways. Advanced glycation end 
products (AGEs), which are increased in diabetes, lead to upregulation and activation of 
the receptor for advanced glycation end products (RAGE). This interaction causes 
inflammation and oxidative stress, through increases in the production of ROS, leading 
to lipid peroxidation. AGEs can also inhibit peroxisome proliferator activated receptor 
(PPAR)γ, a regulator in inflammation as well as the metabolism of lipids and glucose 
[83]. In the study mangiferin also displayed potential as a therapeutic in preventing AGE 
mediated lipogenesis. Antioxidants such as β-carotene, α-tocopherol and ascorbate were 
unsuccessful in reducing incidences of cardiovascular [84] and other diseases such as 
cancer [85], in fact appearing to increase risk in some cases, e.g., with vitamin C, 
x-tocopherol and beta-carotene [86–88]. Antioxidant supplementation to alleviate 
oxidative stress could however be affected by other factors such as the dose of the 
antioxidant, timing of the intervention, interactions with other antioxidants, whether it 
as administered as an isolate or a whole extract, the type of extract, the model as well as 
the methods that are used to detect oxidative stress. Rooibos and honeybush exert 
antioxidant effects by scavenging free radicals, chelating metal ions, or upregulating 
indigenous antioxidant enzymes. The aromatic ring structures of polyphenols also 
contain free hydroxyl groups which contribute to their antioxidant ability. The struc-
tural differences between rooibos polyphenols may thus also explain differences in 
antioxidant activity of these compounds [89]. The antioxidant activity of rooibos and 
honeybush polyphenols may also be explained by their ability to increase the activity of 
antioxidant enzymes, through upregulation of Nrf2, PI3K and other signalling pathways 
involved in cell survival. It may also be explained by their ability to act as antioxidants 
themselves, exerting differential physiological effects. The antioxidant effects of rooibos 
and honeybush and their polyphenols have been extensively studied in detail elsewhere 
and some of these effects are discussed here under the anti-inflammatory, anti-obesity, 
anti-diabetic and cardiovascular effects of these nutraceuticals (Tables 1–4).
6. Anti-inflammatory effects
Inflammation and oxidative stress form a common thread in the metabolic syn-
drome, type 2 diabetes and cardiovascular disease [132, 133]. The rooibos flavonoid 
orientin from rooibos reduced the number of mast cells in colon sections as well as 
N
u
tra
ceu
tica
ls - P
a
st, P
resen
t an
d
 F
u
ture
8
Plant species/compound Model Dosage Mechanistic effects Author and year
C. genistoides; C. subternata; 
C. maculata
Mesenteric lymph 
node cells; murine 
splenocytes
Various up to 250 μg/ml Modulated immune response; increased IFN-γ, IL-4, CD4
+CD25
+FOXP3 TREG 
cells: Total CD4
+ cell ratio in mesenteric lymph node cells; increased IL-10 and 
IL-17a in splenocytes
Murakami et al., 
2018 [90]
ASP; Noth C57BL/6 mouse sepsis 
model
1 mg/kg BW Decreased plasma blood urea nitrogen (BUN), creatinine, urine protein, LDH; 
inhibition of NF-κβ activation; decreased plasma nitric oxide (NO), TNF-α, 
IL-6, myeloperoxidase (MPO) and sepsis associated lethality; decreased 
oxidative stress by increasing kidney superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPx), and decreasing lipid peroxidation
Yang et al., 2018 
[91]
Orientin 1,2-dimethyl hydrazine 
stimulated colorectal 
cancer in Wistar rats
10 mg/kg BW Decreased inflammatory mast cells, NFκ-B, TNFX, IL-6, iNOS and 
cyclooxygenase-2 (COX)-2
Thangaraj and 
Vaiyapuri, 2017 
[92]
C. intermedia; C. subternata UVB/keratinocytes 
(HaCaT)
Various (0.09–0.1 mg/
ml), aqueous extracts; 
0.18-0.71/3 µg/ml, 
methanol extracts
Increased inhibition of cell viability, proliferation induced by UVB (aqueous C. 
intermedia); increased apoptosis, decreased intracellular interleukin (IL) 1-α 
(0.09–0.1 mg/ml); C. subternata (0.09–0.1 mg/ml) increased intracellular IL1-α 
and decreased extracellular IL-1α; methanol extracts alleviated reduction of cell 
growth parameters induced by UVB
Magcwebeba 
et al., 2016 [93]
Honeybush (fermented 
and scale up fermented 
honeybush extracts
HaCaT human 
keratinocyte cells 
exposed to UVB 
irradiation
10–100 μg/ml; 200 μg/ml 
(cell viability)
Anti-inflammatory: Decreased IL-1β, IL-6, IL-8; decreased ERK, P38, 
metallomatrix proteases (MMPs) and C-Jun N-terminal kinase (JNK); increased 
SOD, CAT activities
Im et al., 2016 
[94]
ASP; Noth LPS-induced HUVECs; 
C57BL/6 mice
Various up to 30 µM in 
vitro; ASP 27.1 µg/mouse, 
Noth 26.2 µg/mouse 
in vivo
Inhibition of LPS-induced barrier disruption; decreased expression of cell 
adhesion molecules (CAMs); decreased adhesion/transendothelial migration of 
leukocytes (HUVECs); decreased in vivo LPS-induced migration of leukocytes; 
decreased hyperpermeability; differentially decreased TNF-α, interleukin 
(IL)-6, NF-κB or ERK 1/2 by LPS; decreased LPS-induced lethal endotoxemia; 
increased antioxidant activity, decreased ROS; ASP inhibits effects on anti-
inflammatory responses > Noth
Lee and Bae, 2015 
[95]
C. subternata (scolymoside; 
vicenin-2)
HUVECs; C57BL/6 mice Various up to 20 µM  
in vitro; 23.8 µg/mouse
Decreased adhesion and migration to HUVECS by human neutrophils in vitro, 
in vivo; decreased LPS release of transforming growth factor β-induced protein 
(TGFBIp); decreased TGFBIp mediated hyperpermeability; decreased TNF-α, 
IL-6, NF-κB, extracellular regulated kinases ½
Lee et al., 2015 
[96]
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Plant species/compound Model Dosage Mechanistic effects Author and year
C. subternata flavonoids: 
scolymoside (SCL); vicenin-2 
(VCN)
Human umbilical 
vein endothelial cells 
(HUVECs); C57BL/6 
mice
VCN 11.9 μg/mouse; 
SCL 23.8 μg/mouse 
(±20 μmol/L)
Decreased vascular permeability, monocyte adhesion, CAM expression, NFκ-B 
expression and ROS induced by high glucose; increased expression of SOD, CAT
Ku and Bae, 2015 
[97]
Unfermented rooibos 
(uf) + methanol extracts; 
ASP, Noth
Non-steroidogenic 
transfected COS-1 cells, 
H295R cells
4.3 mg/ml; ASP (10 μm); 
Noth (10 μm)
Decreased steroid production; decreased glucocorticoids during forskolin 
treatment; decreased aldosterone and cortisol precursors (variable effects 
between individual polyphenols and extract)
Schloms et al., 
2012 [27]
Honeybush (fermented, 
green ethanol soluble 
extracts); mangiferin 
(Mangif); hesperidin (Hesp)
SKH-1 mice 30 mg/ml extract; 3 mg/
ml (Hesp); 4 mg/ml 
(Mang): 100 μl applied to 
dorsal skin
Anti-inflammatory: Fermented and unfermented extract decreased oedema, 
epidermal hyperplasia cyclooxygenase-2 (COX-2), ornithine decarboxylase 
(ODC), GADD45 and OGG1/2 expression; fermented extract decreased lipid 
peroxidation by increasing superoxide dismutase, catalase; isolated compounds 
hesperidin and mangiferin less effective than whole extracts
Petrova et al., 
2011 [63]
Rooibos Whole blood cultures 
unstimulated or 
stimulated with 
endotoxins or 
phytohemagglutinin PHA
250–7.8 μg/ml Increased IL-6, 10, IFNγ (unstimulated cells); increased IL-6, decreased IL-10 
(stimulated cells)
Hendricks and 
Pool, 2010 [98]
Rooibos LPS stimulated 
macrophages
0.5 μg/ml Decreased IL-6, IL-10; increased COX2 > 25% Mueller et al., 
2010 [99]
Rooibos Wistar rats (Dextran 
sodium sulphate (DSS) 
induced rat colitis model)
1.6 g/100 ml BW ad 
libitum
Increased SOD vs. DSS rats; decreased 8-hydroxy-2′-deoxyguanosine (8-OHdG) 
vs. controls
Baba et al., 2009 
[100]
Rooibos Murine splenocytes 1–100 μg/ml Increased ovalbumin; increased sheep RBC antibody production; no effect 
on specific LPS stimulated antibody response; increased IL-2 in ova anti-CD3 
primed splenocytes (10–100 μg/ml); decreased IL-4 in ova primed splenocytes; 
increased ova-induced antibody production in cyclosporine A rats; increased 
IL-2 in splenocytes
Kunishiro et al., 
2001 [101]
Extracts are considered fermented unless otherwise indicated.
Table 1. 
Anti-inflammatory and immune modulatory effects of rooibos and honeybush.
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Plant species/
compound
Model Dosage Mechanistic effects Author and 
year
Unfermented 
green rooibos 
extract (GRE)
Human C3A 
liver cells; obese 
insulin-resistant 
rats
10 μg/ml 
(cells); up to 
195 mg/kg 
BW (6 cups), 
rats
Increased 
glucose and lipid 
metabolism: 
Increased glucose 
metabolism in C3A 
cells; increased 
insulin sensitivity in 
OBIR rats: increased 
GLUT2 expression; 
increased PI3K/Akt, 
phosphorylated 
AMPK and 
stimulation of 
insulin receptor 
substrate (IRS) 1, 2 
forkhead box protein 
01 (FOXO1) and 
carnitine palmitoyl 
transferase 1 (CPT1)
Mazibuko-
Mbeje et al., 
2019 [102]
ASP Ventricular 
cardiomyocytes 
isolated from 
healthy, aged 
control and obese 
insulin resistant 
rats
10 μM Increased 
insulin mediated 
glucose uptake in 
cardiomyocytes from 
young and aged rats, 
but not in high-caloric 
diet animals. Insulin 
actions enhanced via 
a PI3K-dependent 
mechanism
Smit et al., 2018 
[103]
ASP; GRE Palmitate-
induced insulin 
resistant 
adipocytes
GRE (10 μg/
ml); ASP 
(10 μM)
Increased GLUT4 
expression (GRE); 
Both treatments: 
decreased lipid-
mediated insulin 
resistance; decreased 
NFκβ, IRS1 (ser307), 
phosphorylated 
AMPK (GRE); 
increased Akt 
phosphorylation; 
Only ASP increased 
peroxisome 
proliferator-activated 
receptor (PPAR) α, γ 
and CPT1
Mazibuko et al., 
2015 [104]
Fermented rooibos 3T3-L1 adipocytes 10 μg/ml, 
100 μg/ml
Decreased lipid 
accumulation; 
decreased 
adipogenesis; 
decreased PPARγ, 
α, sterol regulatory 
binding factor 1 
(SREBF1), fatty acid 
synthase (FASN) 
expression impaired; 
leptin secretion 
decreased
Sanderson 
et al., 2014 
[105]
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Plant species/
compound
Model Dosage Mechanistic effects Author and 
year
Cyclopia maculata 
(aqueous)
3T3-L1 adipocytes 60–100 μg/ml Anti-obesogenic 
60–100 μg/ml 
fermented extracts 
increased glycerol 
release; 80 μg/ml  
increased lipolysis 
maximally; 
increased 
expression of 
perilipin, hormone 
sensitive lipase 
(HSL); not 
cytotoxic  
(up to 100 μg/ml)
Pheiffer et al., 
2013 [106]
Cyclopia maculata 
(fermented, 
fermented), 
Cyclopia subternata 
(unfermented)
3T3-L1 
pre-adipocytes
Various up to 
1600 μg/ml
Anti-obesogenic: 
decreased adipocyte 
differentiation; 
decreased 
intracellular 
triglycerides 
(> 100 μg/ml); 
decreased cellular 
ATP (C. Maculata) 
decreased PPARγ 
isoform 2; increased 
adiponectin 
(fermented C. 
maculata); increased 
leptin cytotoxic: 
800 µg/ml  
(C. maculata 
unfermented), 1600 
µg/ml (C. maculata+ 
C. subternata, 
unfermented)
Dhudhia et al., 
2013 [107]
Rooibos (not 
explicitly stated 
in paper but 
considered to be 
the fermented 
extract)
LDLr−/− mice; 
3T3-L1 adipocytes
10 g/L 
(mice); 
600 μg/ml 
(adipocytes)
Increased lipolysis; 
decreased serum 
cholesterol; 
triglycerides, 
free fatty acids; 
increased food 
consumption in 
mice fed normal 
chow; decreased 
body weight; altered 
adipocyte size, 
number; inhibition 
of dietary-
induced steatosis; 
increased liver 
AMPK; decreased 
triglyceride 
accumulation; 
anti-adipogenic in 
3T3-L1 adipocytes
Beltrán-Debón 
et al., 2011 
[108]
Table 2. 
Anti-obesity effects of rooibos and honeybush.
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Plant species/compound Model Dosage Mechanistic effects Author and 
year
ASP H9c2 Cardiomyocytes; db/db mice 1 μM (cardiomyocytes); 
(13 mg/kg BW)/130 mg/kg 
BW(mice)
Diabetic/cardioprotective/antioxidant; reduced high glucose 
induced oxidative stress; Nrf2-mediated activation of downstream 
antioxidant genes
Dludla et al., 
2017 [64]
ASP Glucose-exposed H9c2 
cardiomyocytes
1 μM Cardioprotective, anti-diabetic, antioxidant effects: Enhanced 
metabolism of glucose, decreased phosphorylation of AMPK, 
decreased CPT1; increased GLUT4, acetyl–CoA carboxylase 
expression; increased glutathione, SOD; decreased ROS, increased 
ucp2, bcl-2: bax; Anti-apoptotic; decreased DNA nicks
Johnson et al., 
2016 [109]
Fermented Cyclopia 
intermedia (methanol 
fermented and scaled up 
extracts
HaCaT human keratinocyte cells 50–100 μg/ml Antioxidant: Increased SOD, CAT in UVB-exposed HaCaT 
keratinocytes
Im et al., 2016 
[94]
Cyclopia subternata (aqueous 
extracts); mangiferin, 
isomangiferin
STZ Wistar rat model; C2C12 cells 30–600 mg/kg (in vivo); 
1 nM–100 μM (isolated 
compounds
Increased glucose tolerance 30, 60, 120 min (600 mg/kg BW; 
mangiferin, isomangiferin increased glucose uptake in C2C12 cells
Schulze et al., 
2016 [110]
ASP; Green rooibos extract 
(GRE)
3T3-L1 adipocytes 100 μM; 10 μg/ml
10 μg/ml
Both isolates decreased palmitate-induced insulin resistance; 
decreased NFκ-β, IRS1 (Ser307), phosphorylated AMPK; increased 
Akt activation; GRE increased GLUT4 expression; ASP increased 
PPARα, γ, CPT1 expression
Mazibuko 
et al., 2015 
[104]
Unfermented rooibos L6 myotubules; RIN-5F Cells; obese 
diabetic KK-Ay mice
350 μg/ml (L6 myotubules); 
50 μg/ml (RIN-5F cells);
0.3–0.6% (mice)
Increased glucose uptake; increased phosphorylated AMPK, Akt; 
increased GLUT4 translocation; decreased AGE-induced ROS 
increase; decreased fasting blood glucose
Kamakura 
et al., 2015 
[111]
Rooibos; Aspalathin (ASP); 
Nothofagin (Noth)
HUVECs; C57BL/6 mice 5–50 μM Cardioprotective/anti-diabetic: Decreased vascular permeability 
caused by high blood glucose, decreased monocyte adhesion; 
Antioxidant: Decreased reactive oxygen species; Anti-
inflammatory: Decreased NFκ-β
Ku et al., 2014 
[112]
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Plant species/compound Model Dosage Mechanistic effects Author and 
year
Fermented rooibos H9c2 cardiomyocytes isolated from 
male Wistar STZ-induced diabetic 
rats (40 mg/kg BW); in vivo, 
ex-vivo rat heart perfusions
1, 10 μg/ml Anti-diabetic/cardioprotective; decreased ROS, apoptosis; 
increased glutathione, metabolic activity in vitro
Dludla et al., 
2014 [113]
Phenylpyruvic acid-2-O-β-
d-glucoside (PPAG)
Obese mice 10 mg/kg Protection from diet-induced hyperglycaemia; increased beta 
cell mass; decreased apoptosis; In vitro, protection of β-cells 
from palmitate-induced apoptosis; increased Bcl-2 expression; 
increased β-cell mass; protective effect of PPAG via increased 
expression of Bcl-2 in β-cells
Mathijs et al., 
2014 [114]
Mangiferin Diabetic insulin resistant Wistar 
rats
20 mg/kg BW No change in body weight; decreased serum glucose; increased 
serum insulin; decreased HOMA IR; increased β-cell function; 
decreased serum TNFα; improved serum lipids; increased 
adiponectin; no effect on antioxidant activity
Saleh et al., 
2014 [115]
Cyclopia maculata 
(unfermented); Mangiferin
RIN-5F cells 0.001–1000 μg/ml (C. 
maculata); 0.01–1000 μg/ml 
(mangiferin)
Increased viability (0.001–1000 μg/ml) Cyclopia; no effect on 
viability (mangiferin)
Chellan et al., 
2014 [116]
Cyclopia maculata STZ-diabetic Wistar rats 30/300 mg/kg BW Increased glucose tolerance; decreased fasting blood glucose; 
improved serum triglycerides; increased β-cell area; increased 
β-cell proliferation (300 mg/kg BW); decreased plasma nitrite; 
unaltered catalase, glutathione, liver lipid peroxidation and 
nitrotyrosine
Z-2-(β-ᴅ-
glucopyranosyloxy)-3-
phenylpropenoic acid 
(PPAG)
Chang cells; Obese insulin-resistant 
rats
1–31.6 μM; 0.3–3 mg/kg BW 
(obese rats)
Increased glucose uptake; decreased fasting blood glucose; 
increased glucose tolerance; increased mRNA expression of liver 
GLUT1, 2, glucokinase, PPARγ and SOCS3
Muller et al., 
2013 [52]
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Plant species/compound Model Dosage Mechanistic effects Author and 
year
ASP L6 myocytes; RIN-5F cells; type 2 
diabetic ob/ob mice
25–100 μM
0.1% ASP (100 mg/kg 
BW); 10 mg/kg BW ASP 
(intraperitoneal glucose 
tolerance test)
Increased glucose uptake; increased AMPK phosphorylation; 
increased GLUT4 translocation in L6 myoblasts and myotubules; 
decreased age-induced ROS; decreased blood glucose; increased 
glucose tolerance; decreased expression of liver gluconeogenic and 
lipogenic gene expression in mice
Son et al., 
2013 [117]
Unfermented green rooibos; 
fermented rooibos
C2C12 skeletal muscle cells 10 μg/ml Increased glucose uptake; increased mitochondrial activity; 
increased ATP (unfermented >fermented); decreased PKCq 
activation; decreased palmitate-induced insulin resistance; 
increased insulin-dependent Akt activation, increased AMP 
Insulin-independent signalling pathways; increased GLUT4
Mazibuko 
et al., 2013 
[118]
ASP; rutin C2C12 myotubules 1,10,100 μM; 100 μm Increased glucose uptake Muller et al., 
2012 [119]
Aspalathin: rutin STZ diabetic rats 1:1 (1.4 mg/kg BW) Decreased blood glucose (not obtained by individual compounds)
Aspalathin rich green 
rooibos
STZ diabetic rats 25 mg/kg BW, 30 mg/kg BW Decreased blood glucose; increased glucose tolerance
Cyclopia intermedia STZ diabetic induced Wistar rats Acute: 5 mg/kg bw-50 mg/kg 
BW (STZ rats)
Decreased fasting blood glucose (50 mg/kg) Muller et al., 
2011 [120]
Obese insulin resistant (OBIR) rats Chronic: 538–2688 mg/ml 
(OBIR rats)
Decreased plasma cholesterol, fasting blood glucose; α:β cell mass 
(538–2150 mg/ml); decreased glucose tolerance (1075–2688 mg/
ml)
ASP from GRE L6 myotubules 1–100 μM Increased glucose uptake Kawano et al., 
2009 [121]
RIN-5F cells 100 μm Increased insulin secretion
db/db mice 0.1–0.2% Decreased fasting blood glucose for 5 weeks; increased glucose 
tolerance 30, 60, 90, 120 min
Fermented rooibos (aqueous 
+ alkaline extracts)
STZ-induced diabetic Wistar rats 2.5% ad libitum Decrease AGE’s + MDA (plasma, lens, liver and kidney); 
decreased total cholesterol and creatinine
Uličná et al., 
2006 [70]
Table 3. 
Anti-diabetic effects of rooibos and honeybush.
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Aspalathin H9c2 cardiomyocytes; db/
db mice
1 μm (cardiomyocytes) 
(13 mg/kg)/130 mg/kg
Diabetic/cardioprotective/antioxidant: reduced high glucose induced 
oxidative stress. Nrf2 activated downstream antioxidant genes; high dose 
aspalathin treatment was more successful than metformin or lower dose 
aspalathin at activating Nrf2 and antioxidant genes
Dludla et al., 
2017 [64]
Aspalathin H9c2 cardiomyocytes 
exposed to glucose
1 μM Cardioprotective/anti-diabetic: Enhanced metabolism of glucose, 
decreased 172 phosphorylated AMPK, decreased carnitine 
palmitoyltransferase (CPT)1, increased GLUT4, acetyl-CoA carboxylase 
expression; antioxidant effects: increased glutathione and SOD, decreased 
ROS, increased UCP2, Bcl-2:Bax; anti-apoptotic; decreased DNA nicks
Johnson et al., 
2016 [109]
Fermented rooibos H9c2 cardiomyocytes 
isolated from male Wistar 
STZ diabetic rats (40 mg/
kg BW)
1/10 μg/ml Decreased ROS, apoptosis, increased glutathione, and metabolic activity 
in vitro
Dludla et al., 
2014 [113]
Luteolin STZ diabetic induced Wistar 
rats
10 µ/kg BW Decreased LDH, incidences of arrhythmias; decreased infarct size; 
increased left ventricular ejection fraction; decreased myocardial 
apoptosis; increased FGFR2, LIF expression; increased PI3K/Akt, Bcl-2 
associated death promoter (BAD), Bcl-2:Bax ratio; inhibited MPO 
expression, IL-6, IL-1a and TNFα production (anti-inflammatory effects)
Sun et al., 2012 
[122]
Luteolin Ischemia/reperfusion (I/R) 
Wistar rats and isolated 
cardiomyocytes
Various up to 40 µM, 
model dependant
Luteolin pre-treatment before I/R injury increased contractions in isolated 
rat heart and cardiomyocytes; decreased LDH, apoptosis; increased Bcl-2: 
Bax ratio; decreased infarct size; protection involves ERK 1/2-PP1a-PLB-
SERCA2a mechanism
Wu et al., 2013 
[123]
Rooibos Human volunteers 400 ml (0.025 g/ml) Single dose inhibited ACE after 30, 60 min; ACE II genotype inhibited 
after 60 min; no effect on nitric oxide
Persson et al., 
2010 [124]
Rooibos HUVEC 0.05 g/ml in phosphate 
buffered saline (PBS)
Increased nitric oxide after 1 day (1:400, 1:200); no effect on ACE 
inhibition after 10 min
Persson et al., 
2006 [125]
Rooibos Human serum with 
Enalaprilat as positive 
control
0.05 g/ml in PBS Inhibition of ACE via a mixed inhibition method Persson et al., 
2012 [126]
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Plant species/compound Model Dosage Mechanistic effects Author and 
year
Rooibos Human volunteers at risk for 
cardiovascular disease
0.005 g/ml (6 cups/day) Increased antioxidant status and decreased oxidative stress by increased 
GSH: GSSG ratio, decreased lipid peroxidation (TBARS, conjugated 
dienes); increased HDL cholesterol
Marnewick 
et al., 2011 
[77]
Orientin Ischemia/reperfused Wistar 
rat hearts; cardiomyocytes 
injured by hypoxia/
reoxygenation
0.5–2 mg/kg BW (rat 
hearts); 3–30 μmol/l 
(cardiomyocytes)
Decreased apoptosis in cardiomyocytes; increased Bcl-2, decreased 
bcl-2-like protein 4 (Bax), increased Bcl-2: Bax; decreased cytochrome-c, 
caspase expression in cardiomyocytes and myocardium
Fu et al., 2006 
[127]
Orientin Ischemia/reperfusion 
injured H9c2 cardiomyocytes
30 μM Decreased apoptosis (decreased MPTP opening) Lu et al., 2011 
[128]
Rooibos (fermented and 
unfermented)
Ex vivo working heart from 
Wistar rats
2% w/v Increased aortic output; decreased cleaved caspase 3, poly (ADP-ribose) 
polymerase (PARP), reduced apoptosis; increased GSH: GSSG ratio
Pantsi et al., 
2011 [129]
Rooibos; chrysoeriol Sprague Dawley rats (blood 
pressure effects); rabbit 
aorta, guinea pig atria
20% w/w, 10–100 mg/
kg BW
Glibenclamide sensitive relaxation of low K+-induced contractions; 
weak inhibitory effect on atrial force and contraction rate; blood 
pressure lowering effects; chrysoeriol caused concentration-dependent, 
glibenclamide-sensitive relaxation of low K+ induced contractions, EC50 
(61 μg/ml), n = 2 in aorta
Khan and 
Gilani, 2006 
[130]
Rooibos and honeybush 
flavonoids (various including 
luteolin, quercetin, rutin, 
genestein, hesperitin, etc.)
In vitro ACE-inhibition assay 500 μM, 100 μM ACE inhibitory activity of some flavonoids found in rooibos and 
honeybush. Luteolin had the greatest ACE inhibitory effects compared to 
the other flavonoids with hesperitin and genestein exhibiting moderate but 
lower, yet marked effects
Guerrero et al., 
2012 [131]
Table 4. 
Cardiovascular effects of rooibos and its flavonoids.
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NFK-β, TNF-α, IL-6, iNOS and COX2, reflecting its anti-inflammatory potential [92]. 
Aspalathin and nothofagin inhibited LPS-mediated expression of the lipopolysaccha-
ride (LPS) receptor (TLR4) and LPS-mediated barrier disruption. This occurred by 
increasing barrier integrity and inhibiting the expression of cell adhesion molecules 
(CAMs) and reducing neutrophil adhesion and migration in human umbilical vein 
endothelial cells [95]. The barrier protective effects of aspalathin and nothofagin were 
confirmed in a mouse model, in which the dihydrochalcones reduced LPS-induced 
mortality. This suggests that aspalathin and nothofagin can be regarded as potential 
therapeutics against vascular inflammation. The protective effects of aspalathin and 
nothofagin in a systemic inflammatory response induced by caecal ligation included 
decreases in inflammatory markers, including TNFα-expression NF-κB, NO and IL-6 
production, enhanced antioxidant activity and decreased lipid peroxidation. [91]. 
The anti-inflammatory effects of rooibos and honeybush may involve a reduction in 
inflammatory cytokines such as IL-6, TNF-α, COX2 [91, 92, 94]. It may also involve a 
reduction in neutrophil adhesion, and other mechanisms [96], Table 1.
7. Anti-obesity effects
Obesity and overweight are major risk factors for cardiovascular disease and 
type 2 diabetes. Insulin resistance, a key finding in the metabolic syndrome, is char-
acterised by alterations in glucose uptake in insulin sensitive tissues such as the liver, 
skeletal muscle and adipose tissue [134]. Non-alcoholic fatty liver disease (NAFLD), 
characterised by fat accumulation in the liver, is an independent predictor of the 
metabolic syndrome which influences the progression of cardiovascular disease 
[135]. Since NAFLD is complex, utilising therapeutic strategies with multiple tar-
gets may be beneficial. The PI3K/Akt pathway is a complex insulin regulated path-
way involved in glucose and lipid metabolism, as well as other cellular processes, 
including protein synthesis, cell signalling cell growth and apoptosis [136]. In type 
2 diabetes and obesity, inhibition of the pathway interferes with beta cell function 
and insulin secretion, exacerbating insulin resistance. A green rooibos extract 
reduced lipid accumulation as well as lipolysis in C3A liver cells [102]. Rooibos also 
ameliorated palmitate-induced insulin resistance, by activating phosphorylated 
PKB/Akt and 5′ adenosine monophosphate-activated protein kinase (AMPK), as 
well as increasing glucose transporter (GLUT)2 expression. Furthermore, fatty 
acid oxidation was enhanced by increasing FOXO1, decreasing malonyl-CoA 
decarboxylase, increasing carnitine palmitoyl transferase 1 (CPT1) and increasing 
acetyl CoA carboxylase in insulin deficient cells. In the accompanying obese insulin 
resistant rat model, only a high dose (195 mg/kg) of green rooibos extract (GRE) 
could reduce insulin levels and the HOMA-IR index. No significant differences were 
detected in blood glucose, body weights or food intake. Insulin receptor and insulin 
receptor substrates 1, and 2 were however upregulated by GRE, suggesting that 
GRE may be beneficial in ameliorating obesity-induced insulin resistance. In 3T-L1 
adipocytes, palmitate-induced insulin resistance was ameliorated by both aspal-
athin, as well as GRE [104]. This was accompanied by increases in Akt activation 
and decreases in nuclear factor (NF)-κB, IRS1 and AMP phosphorylation. GLUT4 
expression was enhanced by the GRE but not aspalathin, suggesting that the whole 
extract rather than the isolated compound may be beneficial in providing a more 
multi-targeted therapeutic approach in improving palmitate-induced effects on 
glucose and lipids. A number of other rooibos polyphenols, such as the C-glycosidic 
flavones orientin, iso-orientin and luteolin, have anti-obesity effects, as reflected 
by their inhibition of pancreatic lipase, which is responsible for digesting and 
absorbing triglycerides [137]. Fermented rooibos also inhibited lipid accumulation 
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in 3T3-L1 adipocytes [105]. Z-2-(β-ᴅ-glucopyranosyloxy)-3-phenylpropenoic 
acid (PPAG), increases glucose uptake, as demonstrated in Chang cells [52]. In 
their in vivo model of obese insulin resistant rats, basal fasting glucose decreased 
and glucose tolerance was improved by PPAG. Increases in mRNA expression of 
genes involved in glucose (GLUT1 and GLUT4) and insulin metabolism (IR) and 
others such as PPARα and SOCS3 in the liver were also seen. PPARα regulates the 
action of fatty acids in the liver, suggesting that insulin signalling, glucose and lipid 
metabolism may be altered by PPAG. SOCS3 associates with various proteins to 
inhibit cytokine signals, e.g., leptin, growth hormone, IL-6, leukaemia inhibitory 
factor (LIF) as well as insulin [138]. It may therefore mediate leptin resistance, 
which occurs in obesity but is also regulated by leptin, which may partially explain 
these findings. Administration of rooibos to LDL receptor deficient (Ldlr−/−) mice 
reduced liver steatosis and white adipose tissue and increased brown adipose tissue 
in high fat diet rats. Macrophage recruitment was decreased but no difference was 
seen in adipocyte size or number in the rooibos supplemented group. Furthermore, 
there appeared to be no liver toxicity, and free fatty acids, triglycerides and choles-
terol were reduced by rooibos in the high fat diet group [108]. In humans, rooibos 
reduced oxidative stress, improved HDL-C, and triacylglycerol and low density 
lipoprotein cholesterol (LDL-C) in adults at risk of developing cardiovascular 
disease. [77]. These results suggest that rooibos and flavonoids in rooibos, such 
as aspalathin, may be potential adjuvants in the management of the metabolic 
syndrome. The anti-obesity effects of Cyclopia intermedia, C. subternata and C. 
maculata are limited but have been studied in 3T3-L1 adipocytes [106, 107, 139]. 
C. maculata and C. subternata decreased intracellular lipid and triglycerides and 
increased PPARγ, a regulator of glucose and lipid metabolism [107]. Their anti-
obesity effects also include increased release of glycerol [106]. Hormone sensitive 
lipase (HSL) expression, which is regulated by SIRT1a, a rate limiter of lipolysis, 
was also increased by fermented C. maculata. Furthermore, perilipin expression, 
which appears to play a key role in the metabolism of lipids and lipolysis of adipose 
tissue was upregulated [140]. C. intermedia increased HSL, SIRT1, UCP3 as well as 
PPARγ expression in 3T3-L1 adipocytes [139]. The authors attributed increases in 
SIRT1 and PPARγ to be indicative of changes from white to brown adipose tissue, 
however the expression of UCP1, which characterises brown adipose tissue was not 
measured in the study [141]. While the exact function is unclear, UCP3 may protect 
against lipotoxicity of the mitochondria [142]. In the parallel obese db/db mouse 
model, no increases in body weight gain were seen with C. intermedia treatment, 
and neither food nor water consumption was affected [139]. Extracts of mangiferin 
and other polyphenols isolated from plants containing components similar to that 
found in honeybush have proven useful in understanding their mechanisms of 
action and how they could be used as nutraceuticals in the treatment of cardiovas-
cular disease. In a double-blind randomised placebo controlled clinical trial, man-
giferin (150 mg/day) from mangoes, was given to 97 overweight, hyperlipidaemic 
patients over a period of 12 weeks. Increased high density lipoprotein cholesterol 
(HDL-C), L-carnitine, as well as decreases in total cholesterol, low density lipopro-
tein cholesterol (LDL-C) and triglycerides were obtained in the patients [143]. No 
alterations in liver and kidney function markers were seen, suggesting that chronic 
treatment over 12 weeks was safe in human participants. Since the metabolic syn-
drome is so complex, providing a multi-targeted approach, such as through affect-
ing the PI3K/Akt pathway may be somewhat beneficial. The anti-obesity effects are 
further described in Table 2. The limited available information on the anti-obesity 
effects of rooibos and honeybush however, suggests that more research is needed to 
fully understand and enable the translation of these effects from animals to man.
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8. Anti-diabetic effects
Diabetic hyperglycaemia involves macro-and microvascular complications [144]. 
Free radicals are also produced, promoting oxidative stress [145]. Evidence suggests that 
rooibos and its polyphenols may reduce oxidative stress associated with the patho-
genesis of diabetes [34, 69]. A meta-analysis and systematic review narrowed down 
to 12 peer-reviewed studies reported a reduction in blood glucose levels in diabetic 
rodent models that had received either rooibos or its polyphenols, while no clinical 
trials have investigated the effects of rooibos in the context of type 2 diabetes [146]. 
Rooibos decreases fasting blood glucose and improves glucose tolerance [117]. The 
anti-diabetic actions may be related to the expression of genes responsible for glucose 
uptake (GLUT1, GLUT2), insulin signalling (IR), as well as other genes such as PPRα in 
the liver in a model of obese insulin resistant rats treated with PPAG [52]. The involve-
ment of insulin dependent GLUT4, in skeletal muscle has also been reported [111]. 
Rooibos may be exerting anti-diabetic effects by affecting the metabolism and uptake 
of glucose. Aspalathin influences key genes involved in the metabolism of lipids, insulin 
resistance, inflammation and apoptosis, possibly reversing metabolic abnormalities by 
involving PPARγ, Adipoq, IL-6/Jak2 pathway and Bcl-2 [74]. PPAG increased beta cell 
mass and delayed hyperglycaemia in STZ-diabetic mice [147]. This was accompanied by 
increases in anti-apoptotic B-cell lymphoma 2 (Bcl-2), but no antioxidant effect, and in 
human islet cells PPAG also decreased cell death. This suggests that PPAG increases beta 
cell mass by decreasing apoptosis and increasing Bcl-2 as reflected in both STZ diabetic 
and obese mouse models [114, 148]. In the absence of insulin, GRE also increased 
phosphorylation of both AMPK and Akt, in L6 skeletal myotubules. Activation of 
AMPK could be a therapeutic strategy in the treatment of obese and type 2 diabetics, 
as animal studies suggest a dysregulation of AMPK in these states. The mechanism 
for the amelioration of diabetic complications in rodents by rooibos and honeybush 
may also be due α-glucosidase inhibition; or SGLT2 inhibiting potential of rooibos and 
honeybush or their respective flavonoids [119, 149–151]. α-Glucosidase is an enzyme 
present on the intestinal brush border where it digests starch, increasing blood glucose 
[152]. Anti-diabetic drugs, therefore commonly utilize strategies such as α-glucosidase 
inhibition or SGLT2 inhibition to facilitate their actions [152, 153]. The dihydrochalcone 
phlorizin, an SGLT2 inhibitor, provides a basis to explore natural plant based agents 
for use in the management of diabetes [154]. Strategies to target SGLT2 rather than 
SGLT1 is also associated with reduced drug toxicity as found in studies of phlorizin and 
anti-diabetic drugs [153]. In an STZ-diabetic model, unfermented extracts of Cyclopia 
maculata improved glucose tolerance, fasting glucose, β-cell area, triglyceride levels as 
well as the insulin: glucagon ratio. Plasma nitrite was reduced but no alterations were 
seen in other markers of nitrotyrosine and lipid peroxidation or the serum antioxidant 
enzymes [155]. Mangiferin and naringenin from Salacia oblonga also reduced blood 
glucose, normalised AST and ALT levels, improved antioxidant status and decreased 
protein carbonyl levels, glycogen and TBARS in the liver. Beta cell damage in the pan-
creas was also ameliorated by the compounds. It was proposed that activation of PPARγ 
and GLUT4, which was also accompanied by insulin sensitisation, may be partially 
responsible for the anti-diabetic effects [156]. Since naringenin is also found in hon-
eybush, it suggests that extracts from honeybush could possibly also produce similar 
effects. Mangiferin from Anemarrhena asphodeloides Bunge reduced blood glucose levels 
and ameliorated hyperinsulinemia, the anti-diabetic properties possibly due to a reduc-
tion in insulin resistance in these rats [157]. Furthermore, mangiferin and naringenin 
isolated from Salacia oblonga reduced blood glucose levels, and increased GLUT4 and 
PPARγ expression, suggesting increased insulin sensitisation and demonstrating the 
anti-diabetic properties of the polyphenols. In conclusion, the anti-diabetic effects of 
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rooibos and honeybush (Table 3) are mediated by complex signalling pathways that 
affect glucose and lipid metabolism as well as oxidative stress.
9. Cardiovascular effects
Angiotensin converting enzyme (ACE) inhibitors reduce blood pressure by 
inhibiting the conversion of angiotensin to angiotensin II, the latter being a potent 
vasoconstrictor which increases blood pressure through a variety of mechanisms [158]. 
Angiotensin II can also interact with the angiotensin I receptor, enhancing ROS 
 production, which contributes to endothelial dysfunction by inactivating vasodila-
tory nitric oxide [158]. Endothelial dysfunction is commonly associated with risk 
factors of cardiovascular disease, including obesity and type 2 diabetes [159]. It also 
precedes atherosclerosis, which involves a number of complex processes such as the 
release of pro-inflammatory cytokines and inflammation, oxidation of LDL as well as 
macrophage recruitment and platelet adhesion [158]. Cardiovascular protective effects 
of rooibos have also been established in a number of studies (Table 4). In an in vitro 
human  umbilical vein endothelial cell (HUVEC) study, rooibos could not inhibit ACE 
but increases in nitric oxide were detected [125]. ACE-inhibition was also determined 
in 17 healthy volunteers receiving a single oral dose of rooibos [124]. Inhibition of ACE 
occurred up to 60 min after ingestion but no change in blood pressure or nitric oxide was 
detected. ACE-inhibitory effects have also been reported for rooibos and honeybush and 
some of their flavonoids [131]. This effect on ACE could be due to the presence of the  
C2〓C3 double bond, the catechol group at the B-ring and the cetone group on C4 on 
the C-ring of flavonoids [131]. The best ACE-inhibitor in HUVEC’s was luteolin, 
followed by quercetin, rutin, kaempferol, rhoifolin and apigenin K. The honeybush 
flavonoids genistein and hesperetin also displayed ACE-inhibitory effects but these were 
less potent than luteolin. Rooibos probably inhibits ACE using a mixed type of inhibi-
tion, which binds to the enzyme’s active and allosteric sites [126]. Organic fractions of, 
as well as flavonoids in rooibos such as chrysoeriol and rutin inhibited spontaneous and 
low and/or high K+-induced contractions in models utilising jejunum and bronchial 
smooth muscle [130, 160]. Anti-contractile effects were reportedly due to the opening 
of K+ channels as well as a Ca2+ antagonistic action. These studies were not done in vas-
cular smooth muscle, but it is possible that rooibos could exert antihypertensive effects 
via similar mechanisms in vascular smooth muscle. It also caused mild reduction of 
atrial force and rate of spontaneous contractions in the Guinea pig and decreased blood 
pressure in anaesthetised rats [130]. In comparison, isolated compounds of rooibos 
tested in jejunal, tracheal and aortic preparations showed variable effects. In adults with 
cardiovascular risk factors, six cups of rooibos was able to increase antioxidant status by 
increasing the GSH: GSSG ratio and decrease lipid peroxidation by decreasing TBARS 
and conjugated dienes [77]. Furthermore, increases in the healthy HDL cholesterol were 
also seen. In a recent study using a high fat diet to induce obesity in Wistar rats, treat-
ment with an enriched GRE, containing large quantities of aspalathin, improved glucose 
tolerance, vascular function, as determined by aortic vascular contraction-relaxation 
studies and enhanced the antioxidant status. Modest improvements in blood pressure 
were also seen in a recent study in obese rats, suggesting cardiovascular benefits with the 
intake of the rooibos [161]. Fermented rooibos also improved vascular function in nico-
tine exposed rats [162]. Since tobacco smoking is a major risk factor for cardiovascular 
disease, this suggests a possible therapeutic role for rooibos in the reduction of cardio-
vascular complications associated with tobacco smoking, such as vascular dysfunction 
or oxidative stress. Cardioprotective effects of rooibos and its flavonoids typically appear 
to involve a reduction in lipid peroxidation and upregulation of the antioxidant enzymes 
through Nrf2 activation, and a reduction in apoptosis which may also be associated with 
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increases in the Bcl-2: Bax ratio [77, 122, 129]. The anti-inflammatory effects of rooibos, 
also support its role as a cardioprotective agent (Table 1). No literature investigating the 
vascular modulating effects of honeybush are currently available and anti-inflammatory 
effects on HUVECs are discussed above. Decreases in VLDL, LDL-C and increases in 
HDL-C by naringenin and mangiferin from Salacia sp. however suggests the potential 
of similar isolates from honeybush to ameliorate endothelial dysfunction [156].
10. Conclusions and perspectives
Rooibos and honeybush have a number of health benefits. The evidence for their use 
as functional nutraceuticals is reflected in anti-diabetic, anti-inflammatory, antioxi-
dant, anti-obesity, and vascular effects in animal and in vitro studies. The translation 
of these results into human medical care has however been limited. The inability to 
translate animal studies to that of humans may be due to the result of the controlled 
genetic background and environmental conditions of animals used as models to study 
disease [163]. Given the unstable nature of ROS and the limitations in assays used to 
detect oxidative stress, it is noteworthy to remember that intervention studies may 
only as good as the biomarkers used to measure the intervention. As we investigate the 
therapeutic role of rooibos or honeybush in the treatment of cardiovascular disease, it is 
evident that we are only but scratching the surface. These plants have complex chemical 
compositions and while isolating single components could be beneficial, the interplay 
and additive effects of other components in whole extracts could be more beneficial 
[111]. The mechanisms behind these benefits involve numerous signalling pathways 
that regulate their effects. Understanding these complexities may be what is needed to 
promote their transition from bush teas to nutraceutical therapy against cardiovascular 
disease but until then we may as well enjoy a cuppa.
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